Internet-based Intervention in Cardioverter-defibrillator Patients to Enhance Quality of Life (WEBCARE)

June 18, 2012 updated by: Dr. SS Pedersen, Tilburg University

WEB-based Distress Management Program for Implantable CARdioverter dEfibrillator Patients (WEBCARE) Trial

The implantable cardioverter defibrillator (ICD) is generally well-accepted by patients, but a subgroup experiences increased anxiety and poor quality of life. A web-based behavioral intervention may comprise a novel approach to reduce anxiety and enhance well-being in ICD patients, which may be equally effective and have advantages over more traditional forms of therapy, due to its low-threshold accessibility via the internet.

The purpose of this study is to determine whether patients receiving a behavioral intervention via the internet experience less anxiety and device concerns and improved quality of life compared to patients receiving usual care.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

350

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Schiedam, Netherlands
        • Not yet recruiting
        • Vlietland Ziekenhuis
        • Contact:
        • Principal Investigator:
          • Suzanne Valk, MD
    • Gelderland
      • Nijmegen, Gelderland, Netherlands, 6500 GS
        • Recruiting
        • Canisius-Wilhelmina Hospital
        • Contact:
        • Principal Investigator:
          • L. Bouwels, MD, PhD
    • Noord Brabant
      • Breda, Noord Brabant, Netherlands, 4800 RL
        • Recruiting
        • Amphia Hospital
        • Contact:
        • Principal Investigator:
          • Marco Alings, MD, PhD
      • Eindhoven, Noord Brabant, Netherlands, 5602 ZA
    • Noord-Holland
      • Amsterdam, Noord-Holland, Netherlands, 1091 AC
        • Recruiting
        • Onze Lieve Vrouwe Gasthuis (OLVG)
        • Contact:
        • Principal Investigator:
          • J.P.R. Herrman, MD, PhD
    • Zuid Holland
      • Rotterdam, Zuid Holland, Netherlands, 3000 CB
        • Recruiting
        • Erasmus Medical Center
        • Contact:
        • Principal Investigator:
          • Luc Jordaens, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients implanted with a cardioverter-defibrillator (ICD)
  • between 18-75 years of age
  • speaking and understanding Dutch
  • with access to the internet and ability to use the internet
  • providing written informed consent

Exclusion Criteria:

  • a life expectancy less than 1 year
  • a history of psychiatric illness other than affective/anxiety disorders
  • on the waiting list for heart transplantation
  • with insufficient knowledge of the Dutch language

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Usual care
12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
Other Names:
  • Cognitive behavioral therapy
  • Psycho-education
  • Relaxation therapy
Experimental: Web-based behavioral intervention
12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
Other Names:
  • Cognitive behavioral therapy
  • Psycho-education
  • Relaxation therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Anxiety
Time Frame: Baseline
Baseline
Anxiety
Time Frame: 14 weeks
14 weeks
Anxiet
Time Frame: 26 weeks
26 weeks
Anxiety
Time Frame: 52 weeks
52 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
Cortisol awakening response
Time Frame: Baseline
Baseline
Cortisol awakening response
Time Frame: 14 weeks
14 weeks
Cortisol awakening response
Time Frame: 52 weeks
52 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Susanne S Pedersen, PhD, Tilburg University, The Netherlands

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2010

Primary Completion (Anticipated)

February 1, 2013

Study Completion (Anticipated)

February 1, 2014

Study Registration Dates

First Submitted

May 7, 2009

First Submitted That Met QC Criteria

May 7, 2009

First Posted (Estimate)

May 8, 2009

Study Record Updates

Last Update Posted (Estimate)

June 19, 2012

Last Update Submitted That Met QC Criteria

June 18, 2012

Last Verified

June 1, 2012

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UVT-MP-001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe